In today’s briefing:
- SK Bioscience (302440 KS): An Attractive Pure-Play on Vaccines- Both COVID and Non-COVID
- Jiangsu Hengrui Medicine (600276.CH) – Here’s when Hengrui May Recover
SK Bioscience (302440 KS): An Attractive Pure-Play on Vaccines- Both COVID and Non-COVID
- SK Bioscience (302440 KS) markets four in-house products in Korea, including influenza, shingles, and chicken pox vaccines. The company has partnerships with global companies for the production of COVID-19 vaccines.
- SK Bioscience has started shipment of Novavax’ COVID-19 vaccine, while its own vaccine is in phase 3 trial. With ~15% vaccination in low-income countries, demand for vaccine is still high.
- SK Bioscience has a rich pipeline, with four promising blockbuster candidates for the global market. This entails strong revenue visibility in post-COVID era.
Jiangsu Hengrui Medicine (600276.CH) – Here’s when Hengrui May Recover
- Entering 2022, Hengrui’s stock price has gone through continuous correction. The market is not that optimistic about the performance of Hengrui in 2021 full year and 2021Q4.
- We analyzed the possible future development trajectory of Hengrui’s performance, which would be up and down due to VBP and NRDL negotiation. Investors could get prepared in advance.
- Due to Hengrui’s “DNA” and development mode, it could have “stable growth” after getting out of the difficult situation, but hard to achieve “explosive growth or significant return”.
Before it’s here, it’s on Smartkarma
